Sramek JJ - Search Results

1

A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase.

Sramek JJ, Block GA, Reines SA, Sawin SF, Barchowsky A, Cutler NR. Sramek JJ, et al. Life Sci. 1995;56(5):319-26. doi: 10.1016/0024-3205(94)00954-6. Life Sci. 1995. PMID: 7837931 Clinical Trial.

2

Galantamine hydrobromide: an agent for Alzheimer's disease.

Zarotsky V, Sramek JJ, Cutler NR. Zarotsky V, et al. Among authors: sramek jj. Am J Health Syst Pharm. 2003 Mar 1;60(5):446-52. doi: 10.1093/ajhp/60.5.446. Am J Health Syst Pharm. 2003. PMID: 12635450 Review.

3

Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism.

Cutler NR, Reines SA, McLean LF, Sramek JJ, Porras AG, Hand EL. Cutler NR, et al. Among authors: sramek jj. Clin Pharmacokinet. 1992 Mar;22(3):223-30. doi: 10.2165/00003088-199222030-00004. Clin Pharmacokinet. 1992. PMID: 1348452

4

Alzheimer's patients should be included in phase I clinical trials to evaluate compounds for Alzheimer's disease.

Cutler NR, Sramek JJ, Murphy MF, Nash RJ. Cutler NR, et al. Among authors: sramek jj. J Geriatr Psychiatry Neurol. 1992 Oct-Dec;5(4):192-4. doi: 10.1177/002383099200500402. J Geriatr Psychiatry Neurol. 1992. PMID: 1418362 Clinical Trial.

5

Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease.

Cutler NR, Sramek JJ, Murphy MF, Nash RJ. Cutler NR, et al. Among authors: sramek jj. Ann Pharmacother. 1992 Sep;26(9):1118-22. doi: 10.1177/106002809202600914. Ann Pharmacother. 1992. PMID: 1421679 Clinical Trial.

6

The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in Alzheimer's disease.

Sramek JJ, Cutler NR, Hurley DJ, Seifert RD. Sramek JJ, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1995 Jan;19(1):85-91. doi: 10.1016/0278-5846(94)00107-s. Prog Neuropsychopharmacol Biol Psychiatry. 1995. PMID: 7535938 Clinical Trial.

7

Safety and tolerability of CI-979 in patients with Alzheimer's disease.

Sramek JJ, Sedman AJ, Reece PA, Hourani J, Bockbrader H, Cutler NR. Sramek JJ, et al. Life Sci. 1995;57(5):503-10. doi: 10.1016/0024-3205(95)00283-c. Life Sci. 1995. PMID: 7623616 Clinical Trial.

8

A "bridging" (safety/tolerance) study of besipirdine hydrochloride in patients with Alzheimer's disease.

Sramek JJ, Viereck C, Huff FJ, Wardle T, Hourani J, Stewart JA, Cutler NR. Sramek JJ, et al. Life Sci. 1995;57(12):1241-8. doi: 10.1016/0024-3205(95)02068-t. Life Sci. 1995. PMID: 7674813 Clinical Trial.

9

Safety and tolerance of intravenous nimodipine.

Sramek JJ, Heller AH, Sundaresan PR, Lettieri J, Sawin S, Cutler NR. Sramek JJ, et al. Ann Pharmacother. 1994 Oct;28(10):1143-8. doi: 10.1177/106002809402801001. Ann Pharmacother. 1994. PMID: 7841566 Clinical Trial.

10

A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder.

Cutler NR, Hesselink JM, Sramek JJ. Cutler NR, et al. Among authors: sramek jj. Prog Neuropsychopharmacol Biol Psychiatry. 1994 May;18(3):447-63. doi: 10.1016/0278-5846(94)90003-5. Prog Neuropsychopharmacol Biol Psychiatry. 1994. PMID: 7915845 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

142 results

Search Page

Filters